Clay B. Siegall's Stock Option Disposal Following Tourmaline Bio Merger

Clay B. Siegall, a director of Tourmaline Bio, Inc., disposed of several stock options following the company's merger with Novartis AG. The merger, completed on October 28, 2025, involved a cash tender offer of $48.00 per share. Siegall disposed of three separate stock options: 20,000 shares at an exercise price of $18.55, 15,000 shares at $13.91, and 16,800 shares at $18.73. These options were automatically canceled and converted into cash payments as per the merger agreement. The transactions were reported under Form 4, indicating no further obligations under Section 16.